Author(s):
During Cervical Cancer Awareness Month, ACCC encourages individuals to share resources, raise awareness, and ensure their loved ones are protected through vaccination.
January is Cervical Cancer Awareness Month, dedicated to educating the public about cervical cancer and emphasizing the importance of early detection and prevention. Cervical cancer begins in the cells of the cervix, the lower part of the uterus that connects to the vagina. It usually develops gradually, starting with precancerous changes in cervical cells. The primary cause of cervical cancer is a persistent infection with high-risk strains of human papillomavirus (HPV), a common sexually transmitted infection.
Regular screening through Pap tests and concurrent HPV testing plays an important role in early detection, as these tests can identify precancerous cell changes, enabling timely treatment and significantly lowering the risk of invasive cervical cancer.
The HPV vaccine works by protecting against the HPV strains most commonly linked to cervical cancer. Gardasil 9, for example, covers 9 HPV types, including those responsible for the majority of cervical cancers. The vaccine has proven highly effective in preventing these high-risk HPV infections. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) recommend routine vaccination for children aged 11 or 12, with the option to start as early as age 9.
Since the introduction of the HPV vaccine, both global and US statistics have shown a significant decrease in cervical cancer rates. In the US, cervical cancer rates among young women have dropped notably, with the largest declines observed in those aged 15 to 20 years. Increased vaccination coverage has been directly correlated with declining cervical cancer incidence and mortality rates. For instance, in the US, the cervical cancer mortality rate among women under age 25 decreased by 62% over the last decade, highlighting the vaccine’s profound impact. Australia stands out as a notable case study; it has nearly eliminated cervical cancer as a public health issue due to its comprehensive vaccination and screening programs.
According to the American Cancer Society, cervical cancer incidence rates have decreased by more than half from the mid-1970s to the mid-2000s, largely due to increased screening. Cervical cancer rates declined by 11% each year from 2012 to 2019 for women aged 20 to 24, likely due to the HPV vaccination. Additionally, the death rate for cervical cancer has dropped by more than half since the mid-1970s because of prevention and screening, although rates have stabilized in recent years. Notably, the death rate in Black women and Native American women is about 65% higher than in White women.
Figure1: Cumulative Incidence of Invasive Cervical Cancer According to HPVVaccination Status (NEJM)
Misinformation and vaccine hesitancy present significant challenges to HPV vaccination efforts. Myths about vaccine safety and unfounded concerns linking the vaccine to increased sexual activity and infertility contribute to reluctance, and are amplified by the widespread use of social media.
Access and health disparities further complicate vaccination efforts, particularly in rural or underserved areas where health care services are limited. Despite programs like Vaccines for Children (VFC) and coverage under the Affordable Care Act (ACA), cost concerns remain a barrier for some families.
Cultural and religious beliefs also play a role, with hesitancy often rooted in deeply held norms and values. Additionally, the lack of strong recommendations from health care providers can lead to lower vaccine uptake, as patients are less likely to get vaccinated without clear guidance from their doctors. Addressing these issues is necessary to improve vaccination rates and reduce the incidence of cervical cancer.
To overcome these barriers to HPV vaccination, a multifaceted approach is essential. Education and awareness campaigns are critical for dispelling myths and misinformation about the vaccine. Public health initiatives can play a significant role in educating communities about the safety and benefits of vaccination. Policy changes and access expansion, such as implementing school vaccination requirements and supporting programs like VFC, can ensure broader vaccine coverage.
Engaging communities and health care providers is also important, as culturally sensitive education programs can address specific concerns and values, while provider education can emphasize the importance of vaccination and encourage strong recommendations to patients. Global collaboration, such as the World Health Organization’s Cervical Cancer Elimination Initiative, can provide a unified effort to reduce cervical cancer rates worldwide. By combining these strategies, vaccination rates can be increased, which can potentially help eliminate cervical cancer as a public health threat.
A promising strategy to reduce barriers to cervical cancer screening is highlighted by a recent study on HPV self-collection. This pilot program, launched in Texas, aims to improve cervical cancer screening in underserved communities by allowing women to collect their own HPV samples. The initiative, conducted by BD, The University of Texas MD Anderson Cancer Center, and Su Clinica, addresses significant barriers, such as limited access to health care resources and cultural hesitancy.
By providing a safe, private, and easy-to-use testing option, the program seeks to increase screening rates among women who may be hesitant or unable to receive traditional screenings. This approach could serve as a model for other regions, ultimately reducing cervical cancer rates and disparities nationwide.
By promoting vaccination and regular screenings, the occurrence of this disease can be significantly reduced. During Cervical Cancer Awareness Month, individuals are encouraged to share resources, raise awareness, and ensure their loved ones are protected through vaccination. These collective efforts can create a meaningful impact on public health and contribute to a future without cervical cancer.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
